EZR and acute myeloid leukemia: These same ezrin inhibitors have recently been shown to reduce cell viability and cell-cycle progression of acute myeloid leukemia (AML) cells (34) and may also demonstrate synergy with chemotherapy and/or targeted therapies used to treat AML.